FDA Adds Boxed Warning to Janssen's Type 2 Diabetes Drug Label
By Zachary Brennan -
Published 16 May 2017
Based on new data from two large clinical trials, the US Food and Drug Administration (FDA) on Tuesday concluded that Janssen’s type 2 diabetes medicine canagliflozin (brand names include Invokana, Invokamet and Invokamet XR) causes an increased risk of leg and foot amputations.
Categories: News, Europe, US, EMA, FDA, MHRA, Clinical, Crisis management, Drugs, Postmarket surveillance
Tags: Janssen, SGLT2 inhibitors, FDA warning